Clinical trial of the neoadjuvant standard chemotherapy 3 FEC [fluorouracil + epirubicin + cyclophosphamide] 100 + 3 Taxotere [docetaxel] protocol versus the same protocol adapted as a function of clinical response

Trial Profile

Clinical trial of the neoadjuvant standard chemotherapy 3 FEC [fluorouracil + epirubicin + cyclophosphamide] 100 + 3 Taxotere [docetaxel] protocol versus the same protocol adapted as a function of clinical response

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2014

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Sep 2014 Status changed from recruiting to completed as per ClinicalTrials.gov record
    • 27 Sep 2011 Interim results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 07 Jun 2011 Interim results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top